Clinical Development Archives - Insights From Our Labs to Yours

Construction workers working on construction site

Sustainability propels innovation and productivity at Labcorp’s newest clinical research unit

by Alex Herringupdated on Tuesday, July 12, 2022Tuesday, July 12, 2022

In early 2023, Labcorp will say farewell to its clinical research unit (CRU) site in Springfield House, Leeds, and open its new CRU in Drapers Yard, Leeds, U.K. The facility offers expanded space for clinical beds and cGMP pharmacy and has also been fit for purpose with several sustainable, energy-saving …

Labcorp Drug Development on the leading edge of revitalizing Leeds’ Temple district

by Alex Herringupdated on Monday, May 23, 2022Monday, May 23, 2022

As a regional leader of life science innovation in the U.K., the city of Leeds abounds in development and innovation potential for the healthcare sector. When considering how best to grow clinical trial operations for 2022 and beyond, Labcorp Drug Development sought to leverage existing location advantages with new opportunities …

Customizing real-world evidence (RWE) study designs: a new framework tool that incorporates elements of virtual study design

by Labcorp Drug Developmentupdated on Monday, June 7, 2021Friday, August 9, 2019

While assisting clients with their clinical development plans, and post-marketing studies, our team is witnessing a trend in designing RWE studies with both traditional and virtual elements. With growing interest in hybrid designs, we are exploring how we can help our clients incorporate their study objectives while evaluating a range …

SEND test submission with Covance. Photo of binary code

Using data visualization tools on SEND datasets: a graph is worth a thousand data points

by Labcorp Drug Developmentupdated on Monday, June 7, 2021Monday, May 20, 2019

SEND [Standard for Exchange of Nonclinical Data] is more than just a tool to facilitate nonclinical data submissions to the FDA. SEND datasets are rich in information, albeit in a form that’s time-consuming for non-experts to parse. With the right visualization tools, SEND data sets can inform nonclinical programs and …

Inflammatory bowel disease clinical studies – where do we go from here?

by Labcorp Drug Developmentupdated on Monday, June 7, 2021Friday, December 14, 2018

Inflammatory bowel disease (IBD), incorporating Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic relapsing-remitting inflammatory disorder of the gastrointestinal tract.1 There is currently no cure for IBD and available treatments (e.g. aminosalicylates, immunosuppressant, biologics) have variable degrees of efficacy and tolerance. As a consequence, there is a large …

A Practical Business Approach to Data Management for Clinical Trial Efficiency

by Labcorp Drug Developmentupdated on Wednesday, May 19, 2021Tuesday, July 11, 2017

Today’s clinical trials have become more complex and expensive, pressuring pharmaceutical companies to further improve their clinical trial operations. Clinical trial data management is one area where both sponsors and contract research organizations (CROs) can uncover new efficiencies, increase cost-saving measures and better meet diverse operational reporting needs across the …

Covance Contract Research Org Biosimilars Webinar 2

A Holistic View of the Biosimilars Landscape: Key Factors for Clinical and Commercial Success

by Labcorp Drug Developmentupdated on Monday, July 26, 2021Wednesday, May 10, 2017

Biosimilars have dominated the headlines in the U.S. with several FDA approvals, legal battles and questions around reimbursement, placing an increased focus on how to successfully navigate this relatively new pathway from end to end. Starting with the regulatory environment to CMC bioanalytics and pharmacodynamics, learn how drug developers can …

The Remarkable Rebirth of Cancer Immunotherapy

by Labcorp Drug Developmentupdated on Sunday, March 29, 2020Wednesday, August 19, 2015

Change is in the Air There’s reason for new hope in the ongoing battle against cancer. From standing-room-only presentations of provocative data at cancer conferences, to landmark publications and new drugs approvals, the signs are multiple and clear. Harnessing the immune system as an anti-cancer therapy–a strategy that has yet …